Latest & greatest articles for ondansetron

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ondansetron or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ondansetron and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ondansetron

1. Risks and benefits of ondansetron for children with acute gastroenteritis

Risks and benefits of ondansetron for children with acute gastroenteritis Risks and benefits of ondansetron for children with acute gastroenteritis Discover Portal Discover Portal Risks and benefits of ondansetron for children with acute gastroenteritis Published on 7 February 2017 doi: Giving ondansetron to children with acute gastroenteritis can stop vomiting, reduce the risk of oral rehydration treatment failing, and reduce the chances of needing intravenous rehydration. But the drug can (...) worsen diarrhoea symptoms. This systematic review looked for evidence about ondansetron’s effectiveness in stopping vomiting and for any impact on diarrhoea or other side effects. Only five out of the 10 included trials reported on diarrhoea related outcomes and they all used different outcome measures so the results could not be combined. This means that although diarrhoea is a recognised side-effect, it is still not known to what extent children given ondansetron may be at risk of recurring

2019 NIHR Dissemination Centre

2. Systematic review and meta-analysis of ondansetron in preventing post-spinal shivering in cesarean delivery

Systematic review and meta-analysis of ondansetron in preventing post-spinal shivering in cesarean delivery Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

3. Single dose of ondansetron versus placebo for vomiting in children and adolescents with acute gastroenteritis

Single dose of ondansetron versus placebo for vomiting in children and adolescents with acute gastroenteritis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

4. Randomized Placebo-controlled Trial of Droperidol and Ondansetron for Adult Emergency Department Patients With Nausea

Randomized Placebo-controlled Trial of Droperidol and Ondansetron for Adult Emergency Department Patients With Nausea The objective was to separately compare effectiveness of 1.25 mg of intravenous (IV) droperidol and 8 mg of IV ondansetron with 0.9% saline placebo for adult emergency department (ED) patients with nausea. A novel primary outcome measure, expected to aid clinical interpretation of reported results, was employed.A randomized controlled trial was conducted at the three EDs (...) that continuation could not result in a finding of superiority.Of 215 patients, 73 (34%), 71 (33%), and 71 (33%) received droperidol, ondansetron, and placebo. Symptom improvement occurred in 75% (95% confidence interval [CI] = 64% to 85%), 80% (95% CI = 69% to 89%), and 76% (95% CI = 64% to 85%), respectively. Mean VAS changes were -29 mm (95% CI = -36 to -23 mm), -34 mm (95% CI = -41 to -28 mm), and -24 mm (95% CI = -29 to -19 mm), respectively. Desired treatment effects were experienced by 77% (95% CI = 65

2019 EvidenceUpdates

5. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. (PubMed)

Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. Evidence for the fetal safety of ondansetron, a 5-HT3 receptor antagonist that is commonly prescribed for nausea and vomiting during pregnancy, is limited and conflicting.To evaluate the association between ondansetron exposure during pregnancy and risk of congenital malformations.A retrospective cohort study nested in the 2000-2013 nationwide Medicaid Analytic eXtract. The cohort (...) trimester, the period of organogenesis.Primary outcomes were cardiac malformations and oral clefts diagnosed during the first 90 days after delivery. Secondary outcomes included congenital malformations overall and subgroups of cardiac malformations and oral clefts.Among 1 816 414 pregnancies (mean age of mothers, 24.3 [5.8] years), 88 467 (4.9%) were exposed to ondansetron during the first trimester. Overall, 14 577 of 1 727 947 unexposed and 835 of 88 467 exposed infants were diagnosed with a cardiac

2018 JAMA

6. Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial

Oral Ondansetron Administration to Nondehydrated Children With Diarrhea and Associated Vomiting in Emergency Departments in Pakistan: A Randomized Controlled Trial We determine whether single-dose oral ondansetron administration to children with vomiting as a result of acute gastroenteritis without dehydration reduces administration of intravenous fluid rehydration.In this 2-hospital, double-blind, placebo-controlled, emergency department-based, randomized trial conducted in Karachi Pakistan (...) , we recruited children aged 0.5 to 5.0 years, without dehydration, who had diarrhea and greater than or equal to 1 episode of vomiting within 4 hours of arrival. Patients were randomly assigned (1:1), through an Internet-based randomization service using a stratified variable-block randomization scheme, to single-dose oral ondansetron or placebo. The primary endpoint was intravenous rehydration (administration of ≥20 mL/kg of an isotonic fluid during 4 hours) within 72 hours

Full Text available with Trip Pro

2018 EvidenceUpdates

7. Ondansetron

Ondansetron Top results for ondansetron - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ondansetron The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

8. Risks and benefits of ondansetron for children with acute gastroenteritis

Risks and benefits of ondansetron for children with acute gastroenteritis Risks and benefits of ondansetron for children with acute gastroenteritis Discover Portal Discover Portal Risks and benefits of ondansetron for children with acute gastroenteritis Published on 7 February 2017 doi: Giving ondansetron to children with acute gastroenteritis can stop vomiting, reduce the risk of oral rehydration treatment failing, and reduce the chances of needing intravenous rehydration. But the drug can (...) worsen diarrhoea symptoms. This systematic review looked for evidence about ondansetron’s effectiveness in stopping vomiting and for any impact on diarrhoea or other side effects. Only five out of the 10 included trials reported on diarrhoea related outcomes and they all used different outcome measures so the results could not be combined. This means that although diarrhoea is a recognised side-effect, it is still not known to what extent children given ondansetron may be at risk of recurring

2018 NIHR Dissemination Centre

9. Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial

Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial We compare aromatherapy with inhaled isopropyl alcohol versus oral ondansetron for treating nausea among emergency department (ED) patients not requiring immediate intravenous access.In a randomized, blinded, placebo-controlled trial, we enrolled a convenience sample of adults presenting to an urban tertiary care ED with chief complaints including nausea (...) or vomiting. We randomized subjects to 1 of 3 arms: inhaled isopropyl alcohol and 4 mg oral ondansetron, inhaled isopropyl alcohol and oral placebo, and inhaled saline solution placebo and 4 mg oral ondansetron. The primary outcome was mean nausea reduction measured by a 0- to 100-mm visual analog scale from enrollment to 30 minutes postintervention. Secondary outcomes included receipt of rescue antiemetic medications and adverse events.We enrolled 122 subjects, of whom 120 (98.3%) completed the study

2018 EvidenceUpdates

10. The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery

The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery Multiple animal studies suggest that ondansetron ameliorates opioid-induced hyperalgesia and tolerance. In this study, we aimed to determine if the administration of ondansetron prior to spinal anesthesia would have an effect on intrathecal opioid-induced acute opioid tolerance, postoperative pain, and analgesic requirements in patients undergoing cesarean delivery (...) with spinal anesthesia.Eighty-six patients undergoing elective cesarean delivery were recruited and randomly allocated to receive either 8 mg intravenous ondansetron (n = 44) or placebo (n = 42) in a prospective, double-blind design. All patients received spinal anesthesia consisting of 15 mg bupivacaine, 20 μg of fentanyl, and 100 μg of preservative-free morphine. We used linear mixed-effects models to assess the difference in pain and opioid consumption in the first 24 hours after surgery between the 2

2017 EvidenceUpdates

11. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2D6</em> genotype and use of ondansetron and tropisetron.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team (...) NGC:011251 2017 Aug NEATS Assessment Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez JAG, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017 Aug;102(2):213-8. [30 references] This is the current

2017 National Guideline Clearinghouse (partial archive)

12. Bringing Up the Best Evidence: Ondansetron in nausea/vomiting of pregnancy

Bringing Up the Best Evidence: Ondansetron in nausea/vomiting of pregnancy Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research (...) . www.acfp.ca July 24, 2017 Bringing Up the Best Evidence: Ondansetron in nausea/vomiting of pregnancy Clinical Question: What are the benefits and risks of ondansetron for nausea and vomiting of pregnancy? Bottom Line: Ondansetron may reduce nausea or vomiting of pregnancy by 25% for one in two users, compared to doxylamine/pyridoxine. There is real uncertainty if ondansetron in pregnancy is associated with any risk to the fetus. Some observational studies suggesting congenital or cardiac defects may

2017 Tools for Practice

13. Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review (PubMed)

Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review To examine the risk of birth defects in children born to women who used ondansetron early in pregnancy for nausea and vomiting of pregnancy or hyperemesis gravidarum.PubMed, EMBASE, Cochrane, Scopus, Web of Science, Journals@Ovid Fulltext, ClinicalTrials.gov, and Google Scholar databases.Studies were included for review if they were written in English, included a comparison population of patients not exposed to ondansetron (...) , and reported human data, original research, exposure to ondansetron during the first trimester, and structural birth defects as an outcome.A total of 423 records were identified. After accounting for duplicate records and including only relevant articles, a total of eight records met criteria for review. Data from the various studies were conflicting: whereas the three largest studies showed no increased risk of birth defects as a whole (36 malformations, 1,233 exposed compared with 141 malformations

Full Text available with Trip Pro

2016 EvidenceUpdates

14. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6 Genotype and Use of Ondansetron and Tropisetron GCBell 1 ,KECaudle 2 ,MWhirl-Carrillo 3 ,RJGordon 4 ,KHikino 5 ,CAProws 6 ,AGaedigk 7 , JAGAgundez 8,9 ,SSadhasivam 10,11 ,TEKlein 3 andMSchwab 12,13,14 The 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antago- nists are used in the prevention (...) of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. CYP2D6 polymorphisms can in?uence the metabolism of some of these drugs (i.e., ondansetron and tropisetron), thereby affecting drug ef?cacy. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for ondansetron and tropisetron based on CYP2D6 genotype (updates at www. pharmgkb.org and cpicpgx.org). The purpose of this guideline is to provide information

2016 Clinical Pharmacogenetics Implementation Consortium

15. Ondansetron and pregnancy: Understanding the data (PubMed)

Ondansetron and pregnancy: Understanding the data Nausea and vomiting of pregnancy (NVP) is a common condition affecting 75% of pregnant women. NVP generally commences early in the first trimester, peaking in severity between 7 and 12 weeks and in over 90% symptoms will have abated by week 20. Thus, the time when women are most likely to have NVP and require treatment coincides with the embryonic period when there is maximum susceptibility to any teratogenic risk. Following the thalidomide (...) tragedy of 55 years ago there is a particular awareness and sensitivity about these potential risks, especially in relation to any medication used to treat NVP. Despite several studies showing no clear benefits of ondansetron over other NVP treatments such as doxylamine, and the paucity of safety data, the off-label prescribing and use of ondansetron to treat NVP has increased significantly worldwide. Albeit based on limited human pregnancy data, ondansetron has not been associated

Full Text available with Trip Pro

2015 Obstetric medicine

16. Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines

Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines Published on: October 7, 2015 Project Number: RA0811-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical (...) effectiveness of ondansetron for children with acute gastroenteritis? What is the clinical effectiveness of ondansetron for adults with acute gastroenteritis? What are the evidence-based guidelines for the use of ondansetron for patients with acute gastroenteritis? Key Message Four systematic reviews, three randomized controlled trials, five non-randomized studies, and two evidence-based guidelines were identified regarding ondansetron use for patients with acute gastroenteritis. Tags antiemetics

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Prophylactic ondansetron for prevention of maternal hypotension following spinal anesthesia in women undergoing cesarean section: a systematic review protocol. (PubMed)

Prophylactic ondansetron for prevention of maternal hypotension following spinal anesthesia in women undergoing cesarean section: a systematic review protocol. 26470663 2018 06 25 2202-4433 13 9 2015 Sep JBI database of systematic reviews and implementation reports JBI Database System Rev Implement Rep Prophylactic ondansetron for prevention of maternal hypotension following spinal anesthesia in women undergoing cesarean section: a systematic review protocol. 84-94 10.11124/jbisrir-2015-2373

2015 JBI database of systematic reviews and implementation reports

18. Effectiveness of ondansetron as an adjunct to lidocaine intravenous regional anesthesia on tourniquet pain and postoperative pain in patients undergoing elective hand surgery: a systematic review protocol. (PubMed)

Effectiveness of ondansetron as an adjunct to lidocaine intravenous regional anesthesia on tourniquet pain and postoperative pain in patients undergoing elective hand surgery: a systematic review protocol. The objective of this quantitative systematic review is to determine the effects of ondansetron as an adjunct to lidocaine on the tourniquet pain and postoperative pain of American Society of Anesthesiologists (ASA) class 1 or 2 adult patients undergoing elective hand surgery with intravenous (...) in the recommended dose range, there are minimal reported side effects, with constipation, dizziness and headache being the most common. 5-HT3 antagonists such as ondansetron possess anti-inflammatory, anesthetic, and analgesic properties which may have a potential role in decreasing pain. 5-HT3 antagonists participate in the pathway of nociception by interfering with peripheral effects of serotonin on nociception. By binding to opioid mu receptors and acting as a potential opioid agonist, the result

2015 JBI database of systematic reviews and implementation reports

19. Ondansetron for Post-Operative Nausea and Vomiting in Elderly Patients

Ondansetron for Post-Operative Nausea and Vomiting in Elderly Patients TITLE: Ondansetron for Post-Operative Nausea and Vomiting in Elderly Patients: Clinical Effectiveness and Safety DATE: 08 August 2014 RESEARCH QUESTIONS 1. What is the clinical effectiveness of intravenous (IV) ondansetron for the prevention and treatment of post-operative nausea and vomiting in elderly patients? 2. What is the clinical evidence regarding the safety and harms of the use of IV ondansetron for the prevention (...) and treatment of post-operative nausea and vomiting in elderly patients? KEY FINDINGS One randomized controlled trial was identified regarding the clinical effectiveness and harms of intravenous (IV) ondansetron for the prevention and treatment of post-operative nausea and vomiting in elderly patients. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 7), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

20. Antiemetic Use for Nausea and Vomiting in Adult Emergency Department Patients: Randomized Controlled Trial Comparing Ondansetron, Metoclopramide, and Placebo (PubMed)

Antiemetic Use for Nausea and Vomiting in Adult Emergency Department Patients: Randomized Controlled Trial Comparing Ondansetron, Metoclopramide, and Placebo We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting.A prospective, randomized, double-blind, placebo-controlled trial was conducted in 2 metropolitan EDs in Melbourne, Australia. Eligible patients with ED nausea and vomiting were randomized (...) to receive 4 mg intravenous ondansetron, 20 mg intravenous metoclopramide, or saline solution placebo. Primary outcome was mean change in visual analog scale (VAS) rating of nausea severity from enrollment to 30 minutes after study drug administration. Secondary outcomes included patient satisfaction, need for rescue antiemetic treatment, and adverse events.Of 270 recruited patients, 258 (95.6%) were available for analysis. Of these patients, 87 (33.7%) received ondansetron; 88 (34.1%), metoclopramide

2014 EvidenceUpdates Controlled trial quality: predicted high